Bdenza 40mg (Enzalutamide)
Description of Bdenza 40mg (Enzalutamide 40mg)
Bdenza 40mg (Enzalutamide 40mg) is a hormonal therapy, for men who are all affected with prostate carcinoma in metastatic stage. Bdenza 40mg (Enzalutamide 40mg) capsules are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. Bdenza 40mg (Enzalutamide 40mg) is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancer. Bdenza 40mg (Enzalutamide 40mg) is a prescription medicine, the main ingredient which is used as enzalutamide, only prescribed by medical oncologist.
INDICATIONS of Bdenza 40mg (Enzalutamide 40mg)
The primary usage of Bdenza 40mg (Enzalutamide 40mg) capsule is involved in the effective treatment of mCRPC (metastatic castration resistant prostate cancer), taken orally. The effect of anti-androgen viewing by obstruct the testosterone production by inhibiting androgen synthesis, the hormone which is require for cancer cell growth. Bdenza 40mg (Enzalutamide 40mg) is majorly used to treat prostate cancer in men.
MECHANISM OF ACTION of Bdenza 40mg (Enzalutamide 40mg)
An androgen which is a male hormone is used to develop prostate carcinoma. One of the major hormone secreted by testes and adrenal glands is known as testosterone. Bdenza 40mg (Enzalutamide 40mg) containing Enzalutamide will interfere with testosterone production, causes tumor cell growth depletion. Bdenza 40mg (Enzalutamide 40mg) interfere with androgen receptor signaling transduction and leads to cancer cell lysis
Absorption of Bdenza 40mg (Enzalutamide 40mg)
After receiving 160mg of Bdenza 40mg (Enzalutamide 40mg) for mCRPC, from median time to attain peak plasma concentration time at 1 hour (variation with 0.5 to 3 hours). The steady state level of Bdenza 40mg (Enzalutamide 40mg) is accomplished by day 28 Food does not cause any alteration in absorption of Bdenza 40mg (Enzalutamide 40mg) capsules.
Distribution of Bdenza 40mg (Enzalutamide 40mg)
Volume of distribution 110L High plasma protein bounding capacity of Bdenza 40mg (Enzalutamide 40mg) capsules is occurs as 97% to 98%
Metabolism of Bdenza 40mg (Enzalutamide 40mg)
Two most prominent cytochrome isoenzymes are involved in metabolism of Bdenza 40mg (Enzalutamide 40mg) capsules; There are two isoenzymes i.e CYP2C8 & CYP3A4; in which CYP2C8 is vital for production of N-desmethyl Enzalutamide which is an active metabolite of Enzalutamide.
Excretion of Bdenza 40mg (Enzalutamide 40mg)
Bdenza 40mg (Enzalutamide 40mg) capsules undergoes excretion by hepatic metabolism Major route of elimination; 71% in urine; 14% in feces The terminal half life period of Bdenza 40mg (Enzalutamide 40mg) capsules is 5.8 days (range at 2.8 to 10.2 days); N-desmethyl Enzalutamide has half life period of relatively 7.8 to 8.6 days.
SIDE EFFECTS of Bdenza 40mg (Enzalutamide 40mg)
Bdenza 40mg (Enzalutamide 40mg) capsules undergoes excretion by hepatic metabolism Major route of elimination; 71% in urine; 14% in feces The terminal half life period of Bdenza 40mg (Enzalutamide 40mg) capsules is 5.8 days (range at 2.8 to 10.2 days); N-desmethyl Enzalutamide has half life period of relatively 7.8 to 8.6 days.
PRECAUTIONS of Bdenza 40mg (Enzalutamide 40mg)
During the treatment with Bdenza 40mg (Enzalutamide 40mg) capsules, patient may suffer with some adverse effects like; Posterior reversible encephalopathy syndrome Seizures In PRES, some neurological disorders occur in patients. The condition can recovered by providing safety measures or discontinue the therapy as soon as possible. PRES is recognized by using MRI In seizures, Before starting the treatment patient must counsel about this adverse reaction and Stop the therapy if possible. Spermatogenesis occurs that may prohibit the male fertility leads to hypo spermatogenesis. In androgen decline the treatment, may have increase exposure of cardiovascular disease like worsening hypertension.
CONTRAINDICATION of Bdenza 40mg (Enzalutamide 40mg)
Bdenza 40mg (Enzalutamide 40mg) capsules are contraindicated to pregnancy condition, which may cause fetal harm leads to death. An Anaphylactic reaction happens, if patients are contraindicated to the ingredient present in Bdenza 40mg (Enzalutamide 40mg) capsules.
PREGNANCY of Bdenza 40mg (Enzalutamide 40mg)
Pregnancy category of Bdenza 40mg (Enzalutamide 40mg) capsule is D Bdenza 40mg (Enzalutamide 40mg) is contraindicated to pregnancy; it may cause fetal harm even to death.
LACTATION of Bdenza 40mg (Enzalutamide 40mg)
Breast feeding is not suggested, Bdenza 40mg (Enzalutamide 40mg) is contraindicated in lactation
DOSAGE of Bdenza 40mg (Enzalutamide 40mg)
The usual prescribed dosage of Bdenza 40mg (Enzalutamide 40mg) is 160mg as a single dose by taking with or without food. Bdenza 40mg (Enzalutamide 40mg) is available in the strength of 40mg; four capsules of Bdenza 40mg (Enzalutamide 40mg) should be administered at a same time. Bdenza 40mg (Enzalutamide 40mg) capsule should not crush, not chew taken with glass of water. Dose adjustment: In patients with ≥ grade III toxicity: Bdenza 40mg (Enzalutamide 40mg) 40mg therapy should be refuse for one week or the symptoms should be reduced to grade II, then restart with same dose or decreased to 80mg or 120mg Strong CYP2C8 inhibitors: While combining with Bdenza 40mg (Enzalutamide 40mg) capsule, the dosage should be modified by reducing to 80mg as a single dose or avoid this combination. Strong CYP3A4 inducers: Co administration of Bdenza 40mg (Enzalutamide 40mg) with Strong CYP3A4 inducers, the dosage of Bdenza 40mg (Enzalutamide 40mg) capsule increased up to 240mg or stop this combination.
STORAGE of Bdenza 40mg (Enzalutamide 40mg)
Bdenza 40mg (Enzalutamide 40mg) capsule container should be stored at the temperature of 20℃ to 25℃ (68℉ to 77℉). Keep the container in cool and dry place Protect from light.
MISSED DOSE of Bdenza 40mg (Enzalutamide 40mg)
If missed a dose the have it as soon possible or Missed dose should be swapped and continue the regular dosing schedule for avoiding adverse conditions. If missed dose occurs, it should not be resume and continue the next schedule.
No reviews found